Skip to content

A Randomized Controlled Trial of Continuous Glucose Monitoring (CGM)-Assisted Weight Loss Intervention in Overweight and Obese Chinese Adults Aged 18 - 24 Years

A Randomized Controlled Trial of Continuous Glucose Monitoring (CGM)-Assisted Weight Loss Intervention in Overweight and Obese Chinese Adults Aged 18 - 24 Years

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106886
Enrollment
Unknown
Registered
2025-07-31
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Intervention Group:Wearing a Continuous Glucose Monitoring (CGM) device for two weeks
Control group:None

Sponsors

Health Science Center, Shenzhen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 24 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18 - 24 years; 2) Meeting at least one of the following criteria, defined as overweight or obese: a. Body Mass Index (BMI) >= 24 kg/m^2 (overweight) or >= 28 kg/m^2 (obese); b. Waist - to - hip ratio: >= 0.90 for males, >= 0.85 for females; c. Body fat percentage: >= 25% for males, >= 30% for females; 3) Capable of using a smartphone and willing to install the relevant app; 4) Informed about the study protocol, willing to participate in the study, and voluntarily signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Age less than 18 years or greater than 24 years; 2) Currently using other weight loss or fat reduction interventions; having received systematic weight loss treatment or taken medications that affect body weight (such as GLP-1 receptor agonists) within the past 3 months; 3) Diagnosed with any chronic diseases; chronic diseases include but are not limited to diabetes, thyroid disorders, cardiovascular diseases, and liver or kidney diseases; 4) Currently taking any medications, including hormonal drugs, psychiatric medications, antidiabetic drugs, or weight loss medications; 5) Pregnant or planning to become pregnant during the study period; 6) History of skin allergies; 7) Unwilling to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Body weight;Body Mass Index;Waist-to-Hip Ratio;Body fat percentage;

Countries

China

Contacts

Public ContactZhang Jing

Shenzhen University

zhangjing1985zj@163.com+86 186 9887 7717

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026